NDAORALTABLETPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
NUPLAZID (pimavanserin tartrate) by Acadia Pharmaceuticals is unclear. First approved in 2016.
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUPLAZID (pimavanserin tartrate) is an oral small-molecule antipsychotic approved in 2016 that functions as an inverse agonist and antagonist at serotonin 5-HT2A and 5-HT2C receptors. It is indicated for psychosis associated with Parkinson's disease and represents a mechanistically distinct approach to treating neuropsychiatric symptoms in this population.
$596MPart D
Peak11.3 years to LOEThe product is at peak commercial performance with $596M in Part D spending and zero direct competitors, indicating a dominant market position that supports stable, well-resourced brand teams.
Mechanism of Action
unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
$596M Medicare spend — this is a commercially significant brand
Worked on NUPLAZID at Acadia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.